Go Pro
→ Your 10X AI demo is starting… (From TradeSmith) (Ad)tc pixel Free CERO Stock Alerts

CERo Therapeutics (CERO) Competitors

CERo Therapeutics logo
$0.01 +0.00 (+17.89%)
As of 08/14/2026 03:36 PM Eastern
Compare

CERO vs. CDT, ASLN, NMTR, ATXI, and EVFM

Should you buy CERo Therapeutics stock or one of its competitors? CERo Therapeutics's main competitors and comparable companies include CDT Equity (CDT), ASLAN Pharmaceuticals (ASLN), 9 Meters Biopharma (NMTR), Avenue Therapeutics (ATXI), and Evofem Biosciences (EVFM). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does CERo Therapeutics compare to CDT Equity?

CDT Equity (NASDAQ:CDT) and CERo Therapeutics (NASDAQ:CERO) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, dividends, media sentiment, risk, profitability, earnings and institutional ownership.

3.3% of CDT Equity shares are owned by institutional investors. Comparatively, 29.6% of CERo Therapeutics shares are owned by institutional investors. 10.8% of CDT Equity shares are owned by insiders. Comparatively, 0.4% of CERo Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

CDT Equity is trading at a lower price-to-earnings ratio than CERo Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CDT EquityN/AN/A-$39.22M-$14.27 thousandN/A
CERo TherapeuticsN/AN/A-$8.30M-$71.01N/A

In the previous week, CDT Equity had 3 more articles in the media than CERo Therapeutics. MarketBeat recorded 3 mentions for CDT Equity and 0 mentions for CERo Therapeutics. CDT Equity's average media sentiment score of 1.32 beat CERo Therapeutics' score of 0.00 indicating that CDT Equity is being referred to more favorably in the media.

Company Overall Sentiment
CDT Equity Positive
CERo Therapeutics Neutral

CDT Equity has a beta of 1.52, meaning that its stock price is 52% more volatile than the broader market. Comparatively, CERo Therapeutics has a beta of 0.13, meaning that its stock price is 87% less volatile than the broader market.

CERo Therapeutics' return on equity of 0.00% beat CDT Equity's return on equity.

Company Net Margins Return on Equity Return on Assets
CDT EquityN/A -72.25% -55.44%
CERo Therapeutics N/A N/A -209.40%

CERo Therapeutics has a consensus price target of $30.00, suggesting a potential upside of 267,757.14%. Given CERo Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe CERo Therapeutics is more favorable than CDT Equity.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CDT Equity
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
CERo Therapeutics
1 Sell rating(s)
2 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.67

Summary

CERo Therapeutics beats CDT Equity on 7 of the 12 factors compared between the two stocks.

How does CERo Therapeutics compare to ASLAN Pharmaceuticals?

CERo Therapeutics (NASDAQ:CERO) and ASLAN Pharmaceuticals (NASDAQ:ASLN) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, risk, earnings, valuation, media sentiment and analyst recommendations.

CERo Therapeutics has higher earnings, but lower revenue than ASLAN Pharmaceuticals. ASLAN Pharmaceuticals is trading at a lower price-to-earnings ratio than CERo Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CERo TherapeuticsN/AN/A-$8.30M-$71.01N/A
ASLAN Pharmaceuticals$12M0.10-$44.22M-$21.92N/A

CERo Therapeutics' return on equity of 0.00% beat ASLAN Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
CERo TherapeuticsN/A N/A -209.40%
ASLAN Pharmaceuticals N/A -8,454.87%-121.60%

CERo Therapeutics has a beta of 0.13, indicating that its stock price is 87% less volatile than the broader market. Comparatively, ASLAN Pharmaceuticals has a beta of 1.4, indicating that its stock price is 40% more volatile than the broader market.

In the previous week, CERo Therapeutics' average media sentiment score of 0.00 equaled ASLAN Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
CERo Therapeutics Neutral
ASLAN Pharmaceuticals Neutral

29.6% of CERo Therapeutics shares are held by institutional investors. Comparatively, 58.8% of ASLAN Pharmaceuticals shares are held by institutional investors. 0.4% of CERo Therapeutics shares are held by insiders. Comparatively, 4.7% of ASLAN Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

CERo Therapeutics currently has a consensus price target of $30.00, suggesting a potential upside of 267,757.14%. Given CERo Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe CERo Therapeutics is more favorable than ASLAN Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CERo Therapeutics
1 Sell rating(s)
2 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.67
ASLAN Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Summary

ASLAN Pharmaceuticals beats CERo Therapeutics on 6 of the 11 factors compared between the two stocks.

How does CERo Therapeutics compare to 9 Meters Biopharma?

9 Meters Biopharma (NASDAQ:NMTR) and CERo Therapeutics (NASDAQ:CERO) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, earnings, profitability, media sentiment, valuation and risk.

In the previous week, 9 Meters Biopharma's average media sentiment score of 0.00 equaled CERo Therapeutics'average media sentiment score.

Company Overall Sentiment
9 Meters Biopharma Neutral
CERo Therapeutics Neutral

CERo Therapeutics' return on equity of 0.00% beat 9 Meters Biopharma's return on equity.

Company Net Margins Return on Equity Return on Assets
9 Meters BiopharmaN/A -584.97% -159.45%
CERo Therapeutics N/A N/A -209.40%

CERo Therapeutics is trading at a lower price-to-earnings ratio than 9 Meters Biopharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
9 Meters BiopharmaN/AN/A-$43.77M-$3.46N/A
CERo TherapeuticsN/AN/A-$8.30M-$71.01N/A

CERo Therapeutics has a consensus target price of $30.00, indicating a potential upside of 267,757.14%. Given CERo Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe CERo Therapeutics is more favorable than 9 Meters Biopharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
9 Meters Biopharma
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
CERo Therapeutics
1 Sell rating(s)
2 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.67

9 Meters Biopharma has a beta of 1.36, indicating that its share price is 36% more volatile than the broader market. Comparatively, CERo Therapeutics has a beta of 0.13, indicating that its share price is 87% less volatile than the broader market.

22.3% of 9 Meters Biopharma shares are held by institutional investors. Comparatively, 29.6% of CERo Therapeutics shares are held by institutional investors. 2.4% of 9 Meters Biopharma shares are held by insiders. Comparatively, 0.4% of CERo Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

9 Meters Biopharma and CERo Therapeutics tied by winning 5 of the 10 factors compared between the two stocks.

How does CERo Therapeutics compare to Avenue Therapeutics?

Avenue Therapeutics (NASDAQ:ATXI) and CERo Therapeutics (NASDAQ:CERO) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, profitability, risk, earnings, dividends and media sentiment.

Avenue Therapeutics has a beta of -0.2, indicating that its stock price is 120% less volatile than the broader market. Comparatively, CERo Therapeutics has a beta of 0.13, indicating that its stock price is 87% less volatile than the broader market.

Avenue Therapeutics is trading at a lower price-to-earnings ratio than CERo Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Avenue TherapeuticsN/AN/A-$10.38M-$0.85N/A
CERo TherapeuticsN/AN/A-$8.30M-$71.01N/A

CERo Therapeutics has a consensus target price of $30.00, indicating a potential upside of 267,757.14%. Given CERo Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe CERo Therapeutics is more favorable than Avenue Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Avenue Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
CERo Therapeutics
1 Sell rating(s)
2 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.67

In the previous week, Avenue Therapeutics' average media sentiment score of 0.00 equaled CERo Therapeutics'average media sentiment score.

Company Overall Sentiment
Avenue Therapeutics Neutral
CERo Therapeutics Neutral

CERo Therapeutics' return on equity of 0.00% beat Avenue Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Avenue TherapeuticsN/A -471.57% -296.50%
CERo Therapeutics N/A N/A -209.40%

17.3% of Avenue Therapeutics shares are owned by institutional investors. Comparatively, 29.6% of CERo Therapeutics shares are owned by institutional investors. 8.6% of Avenue Therapeutics shares are owned by insiders. Comparatively, 0.4% of CERo Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

CERo Therapeutics beats Avenue Therapeutics on 7 of the 10 factors compared between the two stocks.

How does CERo Therapeutics compare to Evofem Biosciences?

CERo Therapeutics (NASDAQ:CERO) and Evofem Biosciences (NASDAQ:EVFM) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, earnings, analyst recommendations, dividends, institutional ownership, valuation and risk.

29.6% of CERo Therapeutics shares are held by institutional investors. Comparatively, 0.2% of Evofem Biosciences shares are held by institutional investors. 0.4% of CERo Therapeutics shares are held by insiders. Comparatively, 0.0% of Evofem Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Evofem Biosciences has higher revenue and earnings than CERo Therapeutics. Evofem Biosciences is trading at a lower price-to-earnings ratio than CERo Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CERo TherapeuticsN/AN/A-$8.30M-$71.01N/A
Evofem Biosciences$11.39M0.09$52.98M-$0.13N/A

CERo Therapeutics presently has a consensus price target of $30.00, suggesting a potential upside of 267,757.14%. Given CERo Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe CERo Therapeutics is more favorable than Evofem Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CERo Therapeutics
1 Sell rating(s)
2 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.67
Evofem Biosciences
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

In the previous week, CERo Therapeutics' average media sentiment score of 0.00 equaled Evofem Biosciences'average media sentiment score.

Company Overall Sentiment
CERo Therapeutics Neutral
Evofem Biosciences Neutral

CERo Therapeutics has a beta of 0.13, meaning that its stock price is 87% less volatile than the broader market. Comparatively, Evofem Biosciences has a beta of -1.32, meaning that its stock price is 232% less volatile than the broader market.

CERo Therapeutics has a net margin of 0.00% compared to Evofem Biosciences' net margin of -46.42%. CERo Therapeutics' return on equity of 0.00% beat Evofem Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
CERo TherapeuticsN/A N/A -209.40%
Evofem Biosciences -46.42%-91.97%-61.93%

Summary

CERo Therapeutics beats Evofem Biosciences on 8 of the 12 factors compared between the two stocks.

Get CERo Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for CERO and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CERO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CERO vs. The Competition

Export
MetricCERo TherapeuticsPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$429K$11.81B$7.03B$13.07B
Dividend YieldN/A2.70%2.57%10.64%
P/E Ratio0.00779.99271.5425.40
Price / SalesN/A948.84673.88125.76
Price / CashN/A89.0475.7053.27
Price / Book0.0011.6012.926.21
Net Income-$8.30M$2.77B$3.45B$347.71M
7 Day PerformanceN/A0.18%1.17%1.08%
1 Month PerformanceN/A0.70%2.18%1.87%
1 Year PerformanceN/A145.73%62.39%20.79%

CERo Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CERO
CERo Therapeutics
N/A$0.01
+17.9%		$30.00
+267,757.1%		-99.9%$429KN/AN/A8
CDT
CDT Equity
1.1479 of 5 stars		$3.14
+9.4%		N/A-99.9%$1.39MN/AN/A3
ASLN
ASLAN Pharmaceuticals
N/A$0.60
flat		N/AN/A$1.23M$12MN/A30
NMTR
9 Meters Biopharma
N/AN/AN/AN/A$1.04MN/AN/A20
ATXI
Avenue Therapeutics
N/A$0.30
-19.0%		N/A-54.8%$990KN/A0.024

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:CERO) was last updated on 8/16/2026 by MarketBeat.com Staff.
From Our Partners
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Man who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown”
In 2016, major election models gave Hillary Clinton a 99% chance of winning - but former CIA and Pentagon advi...
Paradigm Press | Sponsoredtc pixel
Ray Dalio: Buy Gold. Get Paid.
Ray Dalio, founder of Bridgewater Associates, is urging investors to hold 15% of their portfolio in gold and c...
Investors Alley | Sponsoredtc pixel
A Dark Day Is Coming to America
Keith Kaplan, CEO of TradeSmith, has spent more than $17 million studying AI since 2022. He says a major shift...
TradeSmith | Sponsoredtc pixel
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel
Elon admits defeat
Elon Musk just called Anthropic the clear leader in AI, admitting its Mythos model surpasses anything he's bui...
Weiss Ratings | Sponsoredtc pixel
The dollar just broke
Bloomberg research shows the U.S. dollar's share of global reserves has fallen to the lowest level this centur...
Porter & Company | Sponsoredtc pixel
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...
Profits Run | Sponsoredtc pixel